Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 3Thoracic 2Endocrine 2CNS 2Other hematologic neoplasm 1NET 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Somatostatinoma 1Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cytidine Triphosphate × Endocrine × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

NCT01163526 2017-01-30

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford University

Terminated
13 enrolled
EndocrineGastrointestinalNET

Colonic Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neurologic Manifestations, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡